Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

CHNA vs. FSPHX: which is better?

Bottom line

CHNA vs FSPHX: the short answer

CHNA (Loncar China BioPharma ETF) and FSPHX (Health Care Portfolio) are both etfs.

Updated Nov 19, 2026

CHNA vs FSPHX side by side

CHNAFSPHX
TypeETFMutual fund
Fund familyGrayscaleFidelity
CategoryHealth Care SectorHealth Care Sector
Expense ratio—0.62%
Annual cost per $10k—$62
10-yr cost on $10k (prospectus)—$774
Max front loadNone—
12b-1 fee—0%
1-yr return—+14.4%
5-yr return (annualized)—+4.0%
10-yr return (annualized)—+9.0%
Best quarter—+22.2%
Worst quarter—−15.0%
Net assets (fund)—$5.8B
Number of holdings—152
Portfolio turnover—69%
Returns as of—Apr 30, 2026

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

CHNA and FSPHX share none of their top holdings.

CHNA top 10

    FSPHX top 10

    1. ELI LILLY and CO — 8.03%
    2. Danaher Corp — 6.89%
    3. JOHNSON and JOHNSON — 4.91%
    4. Thermo Fisher Scientific Inc — 4.33%
    5. Unitedhealth Group Inc — 3.49%
    6. Alnylam Pharmaceuticals Inc — 2.40%
    7. Gilead Sciences Inc — 2.21%
    8. Boston Scientific Corp — 2.17%
    9. Ascendis Pharma A/s — 2.17%
    10. Fidelity Revere Street Trust — 2.17%

    FAQ

    What is the difference between CHNA and FSPHX?
    CHNA (Loncar China BioPharma ETF) and FSPHX (Health Care Portfolio) are both etfs.
    Should I own both CHNA and FSPHX?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.